• Business Enquiry - enquiry@sthreechemicals.com
Linkedin
Contact Us

Tafamidis Meglumine

Tafamidis Meglumine

VYNDAQEL are indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.

Systematic Name

2-(3,5-Dichlorophenyl)-1,3-Benzoxazole-6-Carboxylic Acid Meglumine

Brand Name(S)

Vyndaqel

Therapeutic Category

Transthyretin amyloidosis

Suitable Formulations

Solid

Approvals

US DMF

EU-WC

Do You Have A Question? Lets Have A Talk

Contact Us

Sthree Chemicals excels in pharmaceutical chemistry, offering quality, reliability, transparency, and trusted partnership for global pharmaceutical success.

Pages

Products

Get In Touch

Enquire now
© Copyright 2023. All Rights Reserved
Linkedin

Sthree chemicals is a pure-play API manufacturer with a diverse portfolio of capabilities in delivering efficiencies to generic players globally. Founded in 2012 by a team with vast experience across the pharmaceutical value chain, the company is on a mission to become the most preferred partner for pharmaceuticals.